What does the evidence say about Hibiscus Blood Pressure Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Hibiscus Blood Pressure Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Conclusion HSE demonstrates the potential to help type 2 diabetic nephropathy patients by modifying renin-angiotensin-aldosterone system activity carbohydrate digestion processes and lipid metabolism which reduces diabetic complications risks. [Kiani M (2026); evidence level 2] - extract (HSE) as a supplemental therapy with valsartan for type 2 diabetic patients with nephropathy and its underlying biological functions were investigated in this study. [Kiani M (2026); evidence level 2] - Materials and methods This clinical trial took place in Gorgan, Iran with 70 diabetic nephropathy patients who had hypertension. [Kiani M (2026); evidence level 2] - This study assessed 8-week changes in Atherogenic and triglyceride-glucose indices (AIP and TyG) after the consumption of a Hibiscus-inulin (HIB-INU) beverage and tested whether baseline risk modified these effects. [Mendivil EJ (2025); evidence level 2] - ANCOVA adjusted for baseline, age, and sex was used to estimate between-group differences and to test for interactions by baseline risk. [Mendivil EJ (2025); evidence level 2] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.